Mn Services Vermogensbeheer B.V. Purchases 3,100 Shares of Stryker Co. (NYSE:SYK)

Mn Services Vermogensbeheer B.V. grew its holdings in Stryker Co. (NYSE:SYK) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 135,100 shares of the medical technology company’s stock after acquiring an additional 3,100 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Stryker were worth $48,643,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. New York Life Investment Management LLC grew its position in shares of Stryker by 0.9% during the 4th quarter. New York Life Investment Management LLC now owns 46,144 shares of the medical technology company’s stock worth $16,614,000 after purchasing an additional 390 shares in the last quarter. NewEdge Wealth LLC boosted its stake in shares of Stryker by 10.5% in the fourth quarter. NewEdge Wealth LLC now owns 6,250 shares of the medical technology company’s stock valued at $2,250,000 after buying an additional 595 shares during the period. Whipplewood Advisors LLC acquired a new stake in Stryker during the fourth quarter worth approximately $169,000. Checchi Capital Advisers LLC increased its stake in Stryker by 1.4% during the 4th quarter. Checchi Capital Advisers LLC now owns 4,024 shares of the medical technology company’s stock worth $1,449,000 after acquiring an additional 56 shares during the period. Finally, Bryn Mawr Capital Management LLC raised its holdings in Stryker by 0.4% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 9,970 shares of the medical technology company’s stock valued at $3,590,000 after acquiring an additional 39 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $391.54 on Thursday. The stock has a fifty day simple moving average of $379.42 and a 200-day simple moving average of $370.37. The stock has a market cap of $149.40 billion, a PE ratio of 50.46, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business posted $3.46 earnings per share. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SYK. BTIG Research increased their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.